Table 1.
Patient baseline characteristics, disease duration, and treatment received.
| Phase | Patient ID | Age, in years | Gender | JIAa subclassification | Disease duration, in years | Current medication |
| I | 1 | 21 | F | Persistent oligoarticular JIA | 17 | Nil. Previously treated with intra-articular steroid injections |
| 2 | 18 | M | ERAb | 3 | Methotrexate (15 mg/m2 scc weekly) | |
| 3 | 17 | M | Persistent oligoarticular JIA | 4 | Nil. Previously treated with intra-articular steroid injections | |
| 4 | 18 | M | ERA | 7 | Etanercept (0.8 mg/kg sc weekly) and methotrexate (15 mg/m2 sc weekly) | |
| 5 | 18 | F | Polyarticular JIA | 15 | Methotrexate (15 mg/m2 sc weekly) and adalimumab (40 mg sc fortnightly) | |
| 6 | 10 | M | Extended oligoarticular JIA | 4 | Methotrexate (15 mg/m2 sc weekly) | |
| 7 | 14 | F | Systemic JIA | 3 | Methotrexate (15 mg/m2 sc weekly) | |
| 8 | 12 | M | Extended oligoarticular JIA | 7 | Nil. Previously treated with intra-articular steroid injections | |
| 9 | 11 | M | Systemic JIA | 2 | Tocilizumab (8 mg/kg fortnightly) and methotrexate (15 mg/m2 sc weekly) | |
| 10 | 12 | F | Psoriatic arthritis | 0.4 | Methotrexate (15 mg/m2 sc weekly) | |
| II | 2 | 18 | M | ERA | 3 | Methotrexate (20 mg/m2 sc weekly) and humira (40 mg sc weekly) |
| 6 | 10 | M | Extended oligoarticular JIA | 5 | Methotrexate (15 mg/m2 sc weekly) | |
| 7 | 14 | F | Systemic JIA | 3 | Methotrexate (15 mg/m2 sc weekly) | |
| 8 | 12 | M | Extended oligoarticular JIA | 7 | Nil | |
| 9 | 12 | M | Systemic JIA | 3 | Tocilizumab (8 mg/kg fortnightly) and methotrexate (15 mg/m2 sc weekly) | |
| 10 | 13 | F | Psoriatic arthritis | 0.8 | Methotrexate (15 mg/m2 sc weekly) | |
| 11 | 23 | F | Bilateral inflammatory hip arthritis | 11 | Methotrexate (10 mg/m2 sc weekly) | |
| 12 | 17 | F | Systemic JIA | 2 | Hydroxychloroquine (400 mg orally daily) | |
| 13 | 20 | F | Persistent oligoarticular JIA | 5 | Methotrexate (20 mg orally weekly) | |
| 14 | 16 | F | Extended oligoarticular JIA | 14 | Methotrexate (15 mg/m2 sc weekly) | |
| 15 | 17 | F | Polyarticular JIA | 9 | Etanercept (25 mg sc weekly) | |
| 16 | 14 | F | Psoriatic arthritis | 12 | Adalimumab (40 mg sc fortnightly) | |
| 17 | 12 | F | Persistent oligoarticular JIA | 8 | Methotrexate (15 mg/m2 sc weekly) | |
| III | 4 | 18 | M | ERA | 8 | Methotrexate (15 mg/m2 sc weekly) |
| 18 | 16 | F | Oligoarticular JIA | 12 | Nil | |
| 19 | 12 | M | Polyarticular JIA | 4 | Methotrexate (25 mg orally weekly) | |
| 20 | 14 | F | Psoriatic arthritis | 8 | Methotrexate (12.5 mg/m2 sc weekly) | |
| 21 | 15 | M | Extended oligoarticular JIA | 8 | Naproxen (500 mg twice a day) | |
| 22 | 17 | F | Extended oligoarticular JIA | 15 | Methotrexate (15 mg/m2 sc weekly) and folic acid (5 mg orally weekly) | |
| 23 | 13 | F | Oligoarticular JIA | 10 | Methotrexate (15 mg/m2 sc weekly) and humira (40 mg fortnightly) | |
| 24 | 15 | F | Systemic JIA | 3 | Methotrexate (27.5 mg/m2 sc weekly), anakinra (150 mg sc daily), and folic acid (5 mg orally weekly) | |
| 25 | 15 | F | Oligoarticular JIA | 4 | Nil | |
| 26 | 23 | M | Extended oligoarticular JIA |
21 | Keppra (500 mg twice a day) | |
| 27 | 15 | F | ERA | 3 | Methotrexate (15 mg/m2 sc weekly) and folic acid (5 mg orally weekly) | |
| 28 | 16 | M | Polyarticular JIA | 1 | Methotrexate (15 mg orally weekly) and folic acid (5 mg orally weekly) | |
| 29 | 18 | F | Polyarticular JIA | 2 | Enbrel (50 mg sc weekly) and methotrexate (7.5 mg orally weekly) |
aJIA: juvenile idiopathic arthritis.
bERA: enthesitis-related arthritis.
csc: subcutaneously.